Literature DB >> 29684916

Predictors of Rapid Cognitive Decline in Patients with Mild-to-Moderate Alzheimer Disease: A Prospective Cohort Study with 12-Month Follow-Up Performed in Memory Clinics.

Achille E Tchalla1,2,3, Jean-Pierre Clément3,4, Isabelle Saulnier1,2,3, Betty Beaumatin1,3, Florent Lachal1,2, Caroline Gayot1, Anaïs Bosetti1, Iléana Desormais4, Anaïck Perrochon2, Pierre-Marie Preux4, Philippe Couratier3,4, Thierry Dantoine1,2,3.   

Abstract

BACKGROUND/AIMS: Alzheimer disease (AD) is particularly devastating, with no cure, no means of prevention, and no proven way to slow progression. AD is associated with the worsening of cognitive function attributable to a variety of factors of which little is known. Our main objective was to determine factors associated with rapid cognitive decline (RCD) in older AD patients.
METHODS: We conducted a 12-month, prospective, multi-centre cohort study. Community-living individuals aged ≥65 years with mild-to-moderate AD were included. RCD was defined as the loss of ≥3 points/year in the Mini-Mental State Examination (MMSE) score. Potential individual-level predictors were collected at baseline.
RESULTS: A total of 521 individuals were included. The mean age was 80.8 ± 9.0 years and 66.0% were females. The average baseline MMSE score was 20.5 ± 4.5. The incidence of RCD was 40.9% (95% confidence interval [CI], 36.7-45.1). RCD was more common in patients with moderate (53.5%) than mild (22.3%) AD. The factors associated with RCD were: a parental history of dementia (odds ratio [OR], 2.32 [95% CI, 1.24-4.21], p = 0.011), psychotic symptoms (OR, 2.06 [95% CI, 1.22-3.48], p = 0.007), malnutrition (OR, 1.61 [95% CI, 1.06-2.63], p = 0.028), and the female gender (OR, 1.48 [95% CI, 1.03-2.15], p = 0.036). An MMSE score < 20 at treatment onset was also associated with RCD (p < 0.001).
CONCLUSION: The factors associated with RCD were an MMSE score < 20 at treatment onset, female gender, psychotic symptoms, malnutrition, and a family history of dementia. These results may be directly relevant to patients, their families, and their physicians, enabling early anticipation of difficult clinical trajectories and poor functional outcomes.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Aging research; Alzheimer disease; Predictive factors; Prevention; Rapid cognitive decline

Mesh:

Year:  2018        PMID: 29684916     DOI: 10.1159/000487938

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  10 in total

1.  Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.

Authors:  G Lombardi; N Lombardi; A Bettiol; G Crescioli; C Ferrari; G Lucidi; C Polito; V Berti; V Bessi; S Bagnoli; B Nacmias; A Vannacci; S Sorbi
Journal:  Eur J Clin Pharmacol       Date:  2022-04-28       Impact factor: 2.953

2.  Drum Communication Program Intervention in Older Adults With Cognitive Impairment and Dementia at Nursing Home: Preliminary Evidence From Pilot Randomized Controlled Trial.

Authors:  Atsuko Miyazaki; Takashi Okuyama; Hayato Mori; Kazuhisa Sato; Masahiko Ichiki; Rui Nouchi
Journal:  Front Aging Neurosci       Date:  2020-07-02       Impact factor: 5.750

3.  Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study.

Authors:  José Manuel Santacruz Escudero; Jonathan Beltrán; Álvaro Palacios; Claudia Marcela Chimbí; Diana Matallana; Pablo Reyes; Victor Perez-Sola; Hernando Santamaría-García
Journal:  Front Aging Neurosci       Date:  2019-07-24       Impact factor: 5.750

4.  High levels of plasma fibrinogen are related to post-stroke cognitive impairment.

Authors:  Yuntao Liu; Huijun Chen; Kai Zhao; Weilei He; Shasha Lin; Jincai He
Journal:  Brain Behav       Date:  2019-09-02       Impact factor: 2.708

Review 5.  Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease.

Authors:  Reena T Gottesman; Yaakov Stern
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

6.  Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease.

Authors:  Mitsunori Watanabe; Yu Nakamura; Yasumasa Yoshiyama; Tatsuo Kagimura; Hiroyuki Kawaguchi; Hiroshi Matsuzawa; Yosuke Tachibana; Kazuma Nishimura; Naoki Kubota; Masato Kobayashi; Takayuki Saito; Kaoru Tamura; Takayuki Sato; Masayoshi Takahashi; Akira Homma
Journal:  Alzheimers Dement (N Y)       Date:  2019-08-29

7.  Anisotropy of Anomalous Diffusion Improves the Accuracy of Differentiating and Grading Alzheimer's Disease Using Novel Fractional Motion Model.

Authors:  Lei Du; Zifang Zhao; Boyan Xu; Wenwen Gao; Xiuxiu Liu; Yue Chen; Yige Wang; Jian Liu; Bing Liu; Shilong Sun; Guolin Ma; Jiahong Gao
Journal:  Front Aging Neurosci       Date:  2020-11-19       Impact factor: 5.750

8.  Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?

Authors:  Ebba Gløersen Müller; Trine Holt Edwin; Bjørn Heine Strand; Caroline Stokke; Mona Elisabeth Revheim; Anne-Brita Knapskog
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

9.  The Impact of the COVID-19 Pandemic on Alzheimer's Disease and Other Dementias.

Authors:  Jinghuan Gan; Shuai Liu; Hao Wu; Zhichao Chen; Min Fei; Junying Xu; Yuchao Dou; Xiaodan Wang; Yong Ji
Journal:  Front Psychiatry       Date:  2021-07-14       Impact factor: 4.157

10.  Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis.

Authors:  Julie Mouchet; Keith A Betts; Mihaela V Georgieva; Raluca Ionescu-Ittu; Lesley M Butler; Xavier Teitsma; Paul Delmar; Thomas Kulalert; JingJing Zhu; Neema Lema; Urvi Desai
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.